Inhibikase Therapeutics Elects Steven C. Gilman, Ph.D., to Board of Directors
Published: May 17, 2011
ATLANTA, May 17, 2011 /PRNewswire/ --Inhibikase Therapeutics, Inc. today announced the election Dr. Steven C. Gilman to the Board of Directors of Inhibikase Therapeutics, Inc.
Dr. Steven Gilman joined Cubist Pharmaceuticals in 2008 and currently serves as the Cubist's Executive Vice President, Research & Development and Chief Scientific Officer. Before joining Cubist Pharmaceuticals, Dr. Gilman held several positions with ActivBiotics, Inc., including Chairman of the board of directors and President and CEO. Previously Dr. Gilman worked at Millennium Pharmaceuticals, Inc., where he held a number of senior leadership roles including Vice President and General Manager, Inflammation. Additionally, Dr. Gilman served as Group Director at Pfizer Global Research and Development, where he was responsible for drug discovery of novel antibacterial agents as well as several other therapeutic areas.
Dr. Gilman currently serves on the Boards of Directors of the Massachusetts Biotechnology Association and the Massachusetts Society for Medical Research. In addition, Dr. Gilman serves on the Science and Regulatory Executive Committee of PhRMA. Dr. Gilman received his Ph.D. and M.S. degrees in microbiology from Pennsylvania State University, his post-doctoral training at Scripps Clinic and Research Foundation, and received a B.A. in microbiology from Miami University of Ohio.
Dr. Gilman joins Board members Dr. Stephen Fesik, Orrin H. Ingram, II Chair in Cancer Research at Vanderbilt University and former Vice-President for Cancer Research, Abbott Laboratories, Mr. David Gryska, former CFO of Celgene and Ms. Lisa Evren, Vice-President and Treasurer, Talisman-Energy.
"We are fortunate to add Dr. Gilman to the slate of new Board members elected in the last eight months. Dr. Gilman's breadth of experience in pharmaceutical development and senior leadership will accelerate Inhibikase's growth and entry into the clinic on a novel platform," said Milton H. Werner, Ph.D., Inhibikase Therapeutics' President and Chief Executive Officer. "The Board is comprised of four leaders in research, development and finance whose insights will be of tremendous value as we build an innovative company and a novel treatment approach for infectious disease."
About Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics is transforming the way pharmaceuticals attack infectious diseases. Its small molecule platform enables treatment of bacterial AND viral infectious disease through a common mechanism of action. The Company's host-targeting strategy using clinically validated drugs and targets treat disease with a low likelihood of stimulating resistance. Founded in 2008 and headquartered in Atlanta, Georgia, Inhibikase Therapeutics is developing treatments for orphan indications arising from polyomaviruses, such as progressive multifocal leukoencephalopathy (PML),as well as a broad range of respiratory infectious diseases, including influenza, pneumonia and respiratory syncitial virus (RSV).
Milton H. Werner, Ph.D.
President and Chief Executive Officer
Inhibikase Therapeutics, Inc.
SOURCE Inhibikase Therapeutics, Inc.